Fennec Pharmaceuticals (FRA:RV41) Total Noninterest Expense

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:RV41 Fennec Pharmaceuticals Inc FRA:RV41
59 GF Score
Price €10.00
GF Value €11.91
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Fennec Pharmaceuticals Total Noninterest Expense?

Total Noninterest Expense only applies to banks.

FRA:RV41
59GF Score
Fennec Pharmaceuticals Inc FRA:RV41
Total Noninterest Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Fennec Pharmaceuticals (FRA:RV41) Overvalued in 2026?

Based on GuruFocus' analysis, Fennec Pharmaceuticals stock appears to be undervalued. The current stock price of €10.00 is trading 16% below its estimated GF Value™ of €11.91. GuruFocus considers Fennec Pharmaceuticals to be Modestly Undervalued.

Key valuation signals for FRA:RV41:

  • Total Noninterest Expense:
  • GF Value™: €11.91 vs. price of €10.00 (16% below fair value)
  • GF Score™: 59/100 with 3 warning signs

No single metric tells the full story. See the FRA:RV41 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Fennec Pharmaceuticals Business Description

Address 68 TW Alexander Drive, PO Box 13628, Research Triangle Park, NC, USA, 27709
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
59GF Score

Get the complete analysis for FRA:RV41

Total Noninterest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€10.00
Price
€11.91
GF Value